Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
Glucagon-like peptide-1 (GLP-1) agonists have taken the healthcare world by storm, emerging as mainstream treatments for patients with diabetes or obesity. Some of these medications include Novo Nordisk's (NYSE: NVO) Ozempic, Wegovy, Rybelsus, and Saxenda, and Eli Lilly's (NYSE: LLY) Mounjaro and Ze